![](https://www.businessmarketinsights.com/assets/img/reports-icon.png)
Prévisions du marché européen des maladies cardiométaboliques jusqu’en 2028 – Impact du COVID-19 et analyse régionale par type (maladie cardiovasculaire (MCV), diabète de type 2, hypertension et obésité), traitement (inhibiteurs de l’ECA, diurétiques, glucophage et autres), posologie (comprimé et injection), voie d\'administration (orale et intraveineuse), utilisateurs finaux (établissements hospitaliers, cliniques et de soins à domicile) et canal de distribution (pharmacie hospitalière, pharmacie de détail et pharmacie en ligne)
Introduction au marché
La maladie cardiométabolique est caractérisée par un groupe d\'anomalies et de symptômes qui soulèvent le risque que les individus développent une maladie cardiovasculaire. L\'hypertension, l\'obésité, la résistance à l\'insuline, la dyslipidémie, un mauvais profil de cholestérol (LDL) et une tolérance au glucose sont quelques-uns des symptômes. Les personnes souffrant du syndrome cardiométabolique sont sujettes à plusieurs autres maladies potentiellement mortelles telles que le diabète de type 2, les accidents vasculaires cérébraux, les maladies coronariennes (MAC), les maladies cardiovasculaires (MCV) et bien d\'autres.
De plus, la prévalence croissante des maladies cardiométaboliques devrait soutenir la croissance du marché au cours de la période de prévision. Cependant, le sous-diagnostic des maladies cardiovasculaires dans les pays à revenu faible et intermédiaire (PRFI) limite la croissance du marché européen des maladies cardiométaboliques.
En Europe, la pandémie de COVID-19 a des conséquences importantes. implications sur les soins cardiovasculaires des patients. Les personnes vivant avec des maladies cardiovasculaires préexistantes courent un risque accru de détérioration de leur santé et de décès en contractant le COVID-19. Les services de prévention, de diagnostic et de traitement des maladies cardiovasculaires ont été gravement perturbés depuis la pandémie de COVID-19. Selon MedTech Europe, environ 95 % de tous les décès dus au COVID-19 avaient au moins une pathologie sous-jacente, les maladies cardiovasculaires étant la principale comorbidité (65 %). En outre, une diminution d\'environ 50 % du nombre de personnes se rendant dans les hôpitaux et autres établissements de santé présentant des symptômes de crise cardiaque ou d\'accident vasculaire cérébral, créant un arriéré important de patients souffrant de problèmes de santé graves. En outre, la réduction des visites aux urgences pour présentation cardiaque par rapport à l’année précédente a chuté entre 31 % et 88 % après le confinement au Royaume-Uni, ce qui a eu un impact négatif sur la croissance du marché. La pandémie a eu un impact significatif sur le marché à court terme ; cependant, le marché connaîtra une croissance modérée au cours de la période de prévision.
Aperçu et dynamique du marché
Le marché européen des maladies cardiométaboliques devrait atteindre 33 963,6 millions de dollars américains d’ici 2028, contre 26 717,5 millions de dollars américains en 2021 ; il devrait croître à un TCAC de 3,5 % de 2021 à 2028. Un outil de risque intégré (IRT), créé par Genomics plc, sera utilisé pour estimer le risque de chaque patient de développer une maladie cardiovasculaire au cours des 10 prochaines années. La société a affirmé que si l\'IRT était appliqué à toute personne âgée entre 40 et 60 ans au Royaume-Uni, elle pourrait identifier plus de 650 000 personnes présentant un risque élevé de maladies cardiovasculaires, omises par le dépistage actuel. En dehors de cela, les progrès récents en matière d’Internet des objets (IoT), de cloud computing et d’intelligence artificielle (IA) ont considérablement amélioré le système de santé conventionnel. En août 2021, les scientifiques de l’Université d’État de l’Oural du Sud (SUSU) ont développé un modèle permettant un diagnostic plus efficace des maladies cardiovasculaires et du diabète, à l’aide de l’IA et de l’IoT. De plus, l’intégration de l’IA offre en outre des opportunités lucratives pour la croissance du marché des maladies cardiométaboliques et devrait continuer à soutenir ce marché au cours de la période de prévision. En juin 2021, l\'ACC et GE Healthcare ont collaboré grâce au soutien et à la participation au Consortium d\'innovation en santé appliquée (AHIC) de l\'ACC pour élaborer une feuille de route pour l\'IA et la technologie numérique en cardiologie et développer de nouvelles stratégies pour améliorer les résultats en matière de santé.
Segments clés du marché
En termes de type, le segment des maladies cardiovasculaires représentait pour la plus grande part du marché européen des maladies cardiométaboliques en 2020. En termes de traitement, le segment des inhibiteurs de l\'ECA représentait la plus grande part du marché européen des maladies cardiométaboliques en 2020. En termes de dosage, le segment des comprimés représentait la plus grande part de le marché européen des maladies cardiométaboliques en 2020. En termes de voie d\'administration, le segment oral représentait la plus grande part du marché européen des maladies cardiométaboliques en 2020. En termes d\'utilisateur final, le segment hospitalier représentait la plus grande part du marché européen des maladies cardiométaboliques. marché des maladies infectieuses en 2020. De plus, sur la base du canal de distribution, le segment de la pharmacie hospitalière détenait la plus grande part de marché en 2020.
Principales sources et sociétés répertoriées
Quelques sources primaires et secondaires majeures mentionnées pour la préparation de ce rapport sur le marché des maladies cardiométaboliques en Europe sont les sociétés sites Web, rapports annuels, rapports financiers, documents gouvernementaux nationaux et bases de données statistiques, entre autres. Les principales sociétés répertoriées dans le rapport sont Eli Lilly and Company., Bayer AG, Novartis AG, Boehringer Ingelheim International Gmbh, Novo Nordisk A/S, AstraZeneca, Alnylam Pharmaceuticals, Inc. et Kowa Company, Ltd.
Rapport sur les raisons d\'acheter
- Comprendre le paysage du marché européen des maladies cardiométaboliques et identifier les segments de marché susceptibles de garantir un fort rendement
- Comprendre le paysage du marché en constante évolution et garder une longueur d\'avance sur la concurrence
- Planifier efficacement les fusions, acquisitions et accords de partenariat sur le marché européen des maladies cardiométaboliques en identifiant les segments avec les ventes probables les plus prometteuses
- Prendre des décisions commerciales éclairées à partir d\'une analyse perspicace et complète des performances du marché de divers segments
- Pour obtenir des prévisions de revenus du marché européen des maladies cardiométaboliques basées sur sur divers segments pour la période 2021-2028
SEGMENTATION DU MARCHÉ DES MALADIES CARDIOMÉTABOLIQUES EN EUROPE
Par Type
- Maladie cardiovasculaire ( MCV)
- Diabète de type 2
- Hypertension
- Obésité
Par traitement
- Inhibiteurs de l\'ECA
- Diurétiques
- Glucophage
- Autres
Par dosage
- Comprimé
- Injection
Par voie d\'administration
- Orale
- Intraveineuse
Par les utilisateurs finaux
- Hôpital
- Clinique
- Paramètres de soins à domicile
Par canal de distribution
- Pharmacie hospitalière
- Pharmacie de détail
- Pharmacie en ligne
Par pays
- Europe
- Allemagne
- Royaume-Uni
- France
- Espagne
- Italie
- Reste de l\'Europe
Entreprises mentionnées
- Eli Lilly et compagnie.
- Bayer AG
- Novartis AG   ;
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Alnylam Pharmaceuticals, Inc.
- Kowa Company, Ltd .
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.7 Europe Cardiometabolic Diseases market – By Country
2. Europe Cardiometabolic Diseases Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Cardiometabolic Diseases Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Expert Opinions
5. Europe Cardiometabolic Diseases Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cardiometabolic Diseases
5.1.2 Innovation in Cardiometabolic Diseases Therapeutics
5.2 Market Restraints
5.2.1 Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs)
5.3 Market Opportunities
5.3.1 Technological Advancements in CMD Diagnosis
5.4 Future Trends
5.4.1 Personalized Treatment for CMDs
5.5 Impact Analysis
6. Europe Cardiometabolic Diseases Market – Regional Analysis
6.1 Europe Cardiometabolic Diseases Market Revenue Forecast And Analysis
7. Europe Cardiometabolic Diseases Market Analysis – By Type
7.1 Overview
7.2 Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
7.3 Cardiovascular Disease (CVD)
7.3.1 Overview
7.3.2 Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Hypertension
7.4.1 Overview
7.4.2 Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.5 Type 2 Diabetes
7.5.1 Overview
7.5.2 Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Obesity
7.6.1 Overview
7.6.2 Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8. Europe Cardiometabolic Diseases Market Analysis – By Treatment
8.1 Overview
8.2 Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
8.3 ACE inhibitors
8.3.1 Overview
8.3.2 ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Diuretics
8.4.1 Overview
8.4.2 Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.5 Glucophage
8.5.1 Overview
8.5.2 Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.6 Others
8.6.1 Overview
8.6.2 Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9. Europe Cardiometabolic Diseases Market Analysis – By Dosage
9.1 Overview
9.2 Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
9.3 Tablet
9.3.1 Overview
9.3.2 Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Injection
9.4.1 Overview
9.4.2 Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
10. Europe Cardiometabolic Diseases Market Analysis – By Route of Administration
10.1 Overview
10.2 Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
10.3 Oral
10.3.1 Overview
10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Mn)
10.4 Intravenous
10.4.1 Overview
10.4.2 Intravenous Market Revenue and Forecast to 2028 (US$ Mn)
11. Europe Cardiometabolic Diseases Market Analysis – By End User
11.1 Overview
11.2 Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
11.3 Clinic
11.3.1 Overview
11.3.2 Clinic Market Revenue and Forecast to 2028 (US$ Mn)
11.4 Hospital
11.4.1 Overview
11.4.2 Hospital Market Revenue and Forecast to 2028 (US$ Mn)
11.5 Homecare Settings
11.5.1 Overview
11.5.2 Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn)
12. Europe Cardiometabolic Diseases Market Analysis – By Distribution Channel
12.1 Overview
12.2 Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
12.3 Hospital Pharmacy
12.3.1 Overview
12.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.4 Retail Pharmacy
12.4.1 Overview
12.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.5 Online Pharmacy
12.5.1 Overview
12.5.2 Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
13. Europe Cardiometabolic Diseases Market – Geographic Analysis
13.1 Europe: Cardiometabolic Diseases Market Revenue and Forecasts to 2028
13.1.1 Overview
13.1.2 Europe: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.3 Europe: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.4 Europe: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.5 Europe: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.6 Europe: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.7 Europe: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.8 Europe: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.9 Europe Cardiometabolic Diseases Market Revenue and Forecasts to 2028, By Country (%)
13.1.9.1 Germany Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.9.1.1 Germany: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.10 Germany: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.11 Germany: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.12 Germany: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.13 Germany: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.14 Germany: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.15 Germany: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.15.1 UK Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.15.1.1 UK; Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.16 UK: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.17 UK: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.18 UK: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.19 UK: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.20 UK: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.21 UK: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.21.1 France Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.21.1.1 France: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.22 France: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.23 France: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.24 France: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.25 France: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.26 France: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.27 France: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.27.1 Italy Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.27.1.1 Italy: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.28 Italy: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.29 Italy: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.30 Italy: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.31 Italy: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.32 Italy: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.33 Italy: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.33.1 Spain Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.33.1.1 Spain Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.34 Spain: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.35 Spain: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.36 Spain: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.37 Spain: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.38 Spain: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.39 Spain: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.39.1 Rest of Europe Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.39.1.1 Rest of Europe: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.40 Rest of Europe: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.41 Rest of Europe: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.42 Rest of Europe: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.43 Rest of Europe: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.44 Rest of Europe: Cardiometabolic Diseases Market, by End User Revenue and Forecast to 2028 (USD Million)
13.1.45 Rest of Europe: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
14. Impact of COVID-19 Pandemic on Europe Cardiometabolic Diseases Market
14.1 Europe: Impact Assessment of COVID-19 Pandemic
15. Europe Cardiometabolic Diseases Market – Industry Landscape
15.1 Overview
15.2 Growth Strategies in the Cardiometabolic Diseases Market (%)
15.3 Organic Developments
15.3.1 Overview
15.4 Inorganic Developments
15.4.1 Overview
16. Company Profiles
16.1 Eli Lilly and Company.
16.1.1 Key Facts
16.1.2 Business Description
16.1.3 Products and Services
16.1.4 Financial Overview
16.1.5 SWOT Analysis
16.1.6 Key Developments
16.2 Bayer AG
16.2.1 Key Facts
16.2.2 Business Description
16.2.3 Products and Services
16.2.4 Financial Overview
16.2.5 SWOT Analysis
16.2.6 Key Developments
16.3 Novartis AG
16.3.1 Key Facts
16.3.2 Business Description
16.3.3 Products and Services
16.3.4 Financial Overview
16.3.5 SWOT Analysis
16.3.6 Key Developments
16.4 Boehringer Ingelheim International GmbH
16.4.1 Key Facts
16.4.2 Business Description
16.4.3 Products and Services
16.4.4 Financial Overview
16.4.5 SWOT Analysis
16.4.6 Key Developments
16.5 Novo Nordisk A/S
16.5.1 Key Facts
16.5.2 Business Description
16.5.3 Products and Services
16.5.4 Financial Overview
16.5.5 SWOT Analysis
16.5.6 Key Developments
16.6 AstraZeneca
16.6.1 Key Facts
16.6.2 Business Description
16.6.3 Products and Services
16.6.4 Financial Overview
16.6.5 SWOT Analysis
16.6.6 Key Developments
16.7 Alnylam Pharmaceuticals, Inc.
16.7.1 Key Facts
16.7.2 Business Description
16.7.3 Products and Services
16.7.4 Financial Overview
16.7.5 SWOT Analysis
16.7.6 Key Developments
16.8 Kowa Company, Ltd.
16.8.1 Key Facts
16.8.2 Business Description
16.8.3 Products and Services
16.8.4 Financial Overview
16.8.5 SWOT Analysis
16.8.6 Key Developments
17. Appendix
17.1 About The Insight Partners
17.2 Glossary of Terms
LIST OF TABLES
Table 1. Europe Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 2. Europe Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 3. Europe Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 4. Europe Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 5. Europe Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 6. Europe Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 7. Germany Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 8. Germany Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 9. Germany Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 10. Germany Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 11. Germany Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 12. Germany Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 13. UK Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 14. UK Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 15. UK Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 16. UK Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 17. UK Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 18. UK Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 19. France Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 20. France Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 21. France Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 22. France Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 23. France Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 24. France Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 25. Italy Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 26. Italy Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 27. Italy Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 28. Italy Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 29. Italy Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 30. Italy Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 31. Spain Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 32. Spain Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 33. Spain Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 34. Spain Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 35. Spain Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 36. Spain Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 37. Rest of Europe Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 38. Rest of Europe Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 39. Rest of Europe Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 40. Rest of Europe Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 41. Rest of Europe Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 42. Rest of Europe Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 43. Organic Developments in the Cardiometabolic Diseases Market
Table 44. Inorganic Developments in the Cardiometabolic Diseases Market
Table 45. Glossary of Terms, Europe Cardiometabolic Diseases Market
LIST OF FIGURES
Figure 1. Europe Cardiometabolic Diseases Market Segmentation
Figure 2. Europe Cardiometabolic Diseases Market Overview
Figure 3. Cardiovascular Disease (CVD) Segment Held Largest Share of Type of Europe Cardiometabolic Diseases Market
Figure 4. Europe Cardiometabolic Diseases Market – Leading Country Markets (US$ Million)
Figure 5. Europe Cardiometabolic Diseases Market, Industry Landscape
Figure 6. Europe PEST Analysis
Figure 7. Europe Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints
Figure 8. Europe Cardiometabolic Diseases Market – Revenue Forecast And Analysis – 2020- 2028
Figure 9. Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
Figure 10. Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 11. Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 12. Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 13. Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14. Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
Figure 15. ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 16. Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 17. Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 18. Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 19. Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
Figure 20. Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 21. Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 22. Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
Figure 23. Oral Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 24. Intravenous Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 25. Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
Figure 26. Clinic Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 27. Hospital Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 28. Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 29. Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
Figure 30. Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 31. Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 32. Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 33. Europe: Cardiometabolic Diseases Market Revenue Overview, by Country, 2021 (US$ MN)
Figure 34. Europe Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 35. Europe Cardiometabolic Diseases Market Revenue and Forecasts to 2028, By Country (%)
Figure 36. Germany: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 37. UK: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 38. France: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 39. Italy: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 40. Spain Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 41. Rest of Europe: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 42. Impact of COVID-19 Pandemic on Europe Cardiometabolic Diseases Market
Figure 43. Growth Strategies in the Cardiometabolic Diseases Market (%)
- Eli Lilly and Company.
- Bayer AG
- Novartis AG
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Alnylam Pharmaceuticals, Inc.
- Kowa Company, Ltd
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe cardiometabolic diseases market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.